Don't Get Lost
in a Sea of Data…

Qlarant Can Help.

*Data Management and Analysis
to Enhance the Drug Enforcement
Agency Diversion Program*

Qlarant

Don't Get Lost in a Sea of Data... Qlarant Can Help

Drug diversion is a common practice tied closely to the extensive opioid epidemic problem that faces our country today. The Drug Enforcement Administration (DEA) is charged with the daunting task of ensuring that properly and legally manufactured drugs are distributed and managed in a manner that ensure that they are provided by the intended distributers to their properly prescribed patients. As part of that effort, DEA executes criminal and administrative warrants to seize or acquire medical records from doctor's offices and pharmacy records from pharmacies as evidence of violations of the Controlled Substance Act.

Making sense of the mountain of data can be a daunting task—one that takes time away from the efforts of law enforcement. The indicators of fraudulent activity or diversion tactics are often deeply buried and hidden in this data. The sooner this information can be deciphered, the sooner the DEA can take action against the root causes of the opioid crisis. Qlarant has the knowledge, skills, and abilities derived from many years of fraud investigations using data analytics to take on this challenge for the DEA.

Powerful Solutions that Support DEA Investigation Efforts

Qlarant, one of the nation's leading experts in detecting fraud, waste, and abuse (FWA), has the expertise and experience to provide "punch" to the DEA's Diversion Control efforts. By combining state-of-the-art technology and data analytics with extensive subject-matter expertise, Qlarant can sift through these records and provide the information necessary to maximize the DEA's law enforcement efforts.

Targeted Data Analysis

When using Prescription Drug Monitoring Data (PDMP) records to investigate a specific provider, Qlarant will conduct a thorough and detailed analysis of the provider to bring clarity to the complexity of the volumes of data available. Qlarant's sophisticated analytics and subject matter expert review will highlight aberrant behavior and indicate the likelihood of diversion. These actions can detail:

- The number of CII prescriptions
- Pill counts
- The distance a patient drives
- The number of prescriptions written per month

- Instances of distributor "crew chief" schemes
- Pre-seizure identification of the most likely drug-seeking patients
- And other customized selections

Qlarant can sort, combine, coordinate, analyze, and summarize mountains of data so you don't have to!

Onsite Support Gathering Evidence
Qlarant can accompany DEA agents and investigators on the day they execute warrants on a provider's record retrieval system to seize electronic medical records (EMRs). Qlarant can mirror the EMR hard drive, allowing for quick retrieval of all the data for further analysis and review. Qlarant's experienced technicians will accompany DEA agents and investigators executing warrants on a provider's office and—using previously identified patients from the PDMP data analysis—can digitally scan the identified medical records into an electronically retrievable format.

Expert Clinical Review and Testimony
Qlarant has more than 45 years of experience conducting medical records review. Our team has conducted thousands of medical records reviews for:

- The US Department of Health and Human Services
- The Office of the Inspector General (HHS/OIG)
- The Centers for Medicare & Medicaid Services (CMS)
- United States Attorney's Offices
- State Departments of Health

Qlarant leverages the extensive knowledge of our qualified medical experts to determine if providers have over-prescribed controlled substances. Federal and state agencies continue to rely on Qlarant to provide expert testimony in court cases because of our excellent track record of assisting law enforcement to achieve convictions in high-profile litigations.

Qlarant—See Risks. Solve Problems. Seize Opportunities.

A Rich Resource of Experts
Qlarant employs a force of over 500 highly skilled associates with extensive experience in human services and health care. We focus on a variety of healthcare topics—including data analytics; risk scoring; and FWA detection and pursuit—through our partnership with federal and state enforcement entities. Qlarant's partners include HHS/OIG, the Federal Bureau of Investigation (FBI), and the DEA.

Qlarant drives and transforms business problems into business solutions. This is possible through the unique collaboration of respected professionals with specialized skills—such as credentialed data scientists and subject matter experts. Our talented staff includes:

- Auditors
- Compliance experts
- Former law enforcement and state Medicaid officials
- Physicians
- Policy experts

- Senior nurses
- Investigators
- Pharmacists
- Epidemiologists
- Data scientists
- Claims and data analysts

We also provide premier consulting services to assist our clients, working together with other collaborative law enforcement bodies, in utilizing data findings and providing the tools and support for successful prosecutions or other legal challenges.

Qlarant's clinical pharmacy experts bring a wide range of experience in dealing with the opioid epidemic. Our pharmacists have several decades of experience in both traditional and non-traditional pharmacy practice settings in addition to their current work ferreting out FWA schemes for CMS. Qlarant has developed multiple data analysis projects and predictive analytic tools to aid in the detection of opioid misuse and abuse. These projects have focused on enhancing education, awareness, and oversight at all levels of the drug distribution chain.

Qlarant Leads the Industry
Qlarant is an industry leader in conducting predictive modeling and analytics. Our expert team of pharmacists, data scientists, and investigators work together to develop key risk indicators and algorithms to be applied to data files looking for patterns and questionable behaviors and interactions.

Your Partner Deterring Diversion
All of these qualities provide Qlarant with substantial experience on a national level at reviewing key metrics to identify outliers for prosecution and enforcement initiatives. Qlarant can provide the DEA with the tools and information to identify and stop drug diversion in its tracks.

For more information contact:

Sandy Love, President
Qlarant Integrity Solutions
28464 Marlboro Avenue, Easton, MD 21601
410-763-6242
loves@qlarant.com

QLARANT
INTEGRITY SOLUTIONS
Easton, Maryland
QSR-1106 for the ISO 9001:2015
Quality Management System Standards

CMMI DEV /3℠
Exp. 2020-12-15 | Appraisal #30011

TOP WORK PLACES 2017-2018
THE BALTIMORE SUN MEDIA GROUP

Qlarant